key: cord-0689360-b9fxrt0z
authors: Klonoff, David C.; Umpierrez, Guillermo E.
title: COVID-19 in patients with diabetes: risk factors that increase morbidity
date: 2020-04-07
journal: Metabolism
DOI: 10.1016/j.metabol.2020.154224
sha: 1352a96368d1bb8b48de2feb413d0ee0dd56333f
doc_id: 689360
cord_uid: b9fxrt0z

nan

Susceptibility to hyperglycemia from corticosteroid therapy. This therapy raises glucose levels in 80% of patients with diabetes and in many patients without diabetes, which could increase mortality risk in coronavirus infections. (2) Corticosteroids are not indicated in all severely ill patients with COVID-19. The Surviving Sepsis Campaign recommendations recommends using corticosteroids for mechanically ventilated patients in specific situations rather than routinely. (See Table 1 ) If corticosteroids are necessary, then glucose levels should be treated vigorously to maintain near euglycemia aimed at maintaining optimal pulmonary and immunologic function. (3) 2) Inadequate glucose monitoring. Optimal hospital glycemic control requires frequent blood glucose (BG) tests. (4) For COVID-19 patients a nurse must wear personal protective gear for fingersticking. In some cases, a nurse will not have time or adequate protective equipment resulting in suboptimal testing. Some physicians will order infrequent testing to minimize direct contact between the nurse and patient. In some hospitals, trials are underway to use continuous glucose monitoring (CGM) systems (5) to minimize contact. Currently, no CGM is cleared for use in the hospital so this method cannot be recommended outside of a clincal trial.

Lack of contact with healthcare professionals. COVID-19 patients with diabetes will be quarantined and unable to visit their physicians. (6) Over 50 U.S. health systems now have telemedicine programs. that allow clinicians to see patients who are at home. (7) More contact with physicians will help quarantined COVID-19 patients improve their glucose control. In mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS), we suggest against the routine use of systemic corticosteroids. Weak recommendation, low-quality evidence.

In mechanically ventilated adults with COVID-19 and ARDS, we suggest using systemic corticosteroids, over not using corticosteroids. Weak recommendation, low-quality evidence. Remark: The majority of our panel support a weak recommendation (i.e. suggestion) to use steroids in the sickest patients with COVID-19 and ARDS. However, because of the very low-quality evidence, some experts on the panel preferred not to issue a recommendation until higher quality direct evidence is available.

Commentary: COVID-19 in Patients with Diabetes

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Coalition for Clinical Research-Self-Monitoring of Blood Glucose Scientific Board. Consensus report: the current role of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes

Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital

Virtually Perfect? Telemedicine for Covid-19

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Virtually Perfect? Telemedicine for Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19